WuXi Biologics and Aravive Collaborate to Develop Novel High-Affinity Bispecific Antibodies for Cancer and Fibrosis

Wuxi Biologic; Acquire; Bayer; Production Facility; Germany


  • The collaboration leverages WuXi’s WuXiBody platform to develop high-affinity bispecific Ab targeting CCN2 for the treatment of cancer and fibrosis
  • WuXi Biologics will be responsible for biologics discovery, process development, and manufacturing, whereas Aravive will be responsible for pre/ clinical development
  • In 2018, Aravive and WuXi Biologics expanded their manufacturing collaboration for development and manufacturing of AVB-500 following the US FDA’s IND filing of AVB-500

Click here to­ read full press release/ article | Ref: PRNewswire  | Image: Wuxi Biologics